Autopsy report · NCT04824794

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

“The sponsor has decided to discontinue further development of GEN3014 after a comprehensive review of the data, market landscape, and strategic priorities.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 5 months before it stopped.
• 130 participants enrolled.
• Results were posted on the registry 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Genmab

Sponsor type

Industry

Conditions

Relapsed or Refractory Multiple Myeloma (RRMM); Diffuse Large B Cell Lymphoma (DLBCL); Acute Myeloid Leukemia (AML)

Interventions

GEN3014; Daratumumab

Participants

130

Sites

52

Countries

Australia, Bosnia and Herzegovina, Czechia, Denmark, France, Georgia, Greece, Hungary, Malaysia, Moldova, Netherlands, New Zealand and more

Trials that died the same way

• Study of Satraplatin (JM-216) in Combination With Docetaxel
  “Sponsor decided to discontinue study drug development.” (61% match in meaning)
• A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
  “Early discontinuation based on strategic sponsor decision not driven by any safety concerns” (60% match in meaning)
• Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
  “Sponsor decided to discontinue the study due to strategic considerations and not due to any safety-related concerns.” (59% match in meaning)
• Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults
  “sponsor decided to withdrawn the study as development strategy has changed” (57% match in meaning)
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）
  “Due to adjustments in the sponsor's development strategy, it has been decided to terminate the study.” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.